U.S. Biotech Expands Cardiovascular New Drugs, Acquires Nasal Spray and Reveals Revenue Growth

Esperion Therapeutics, Inc. (ESPR) reported double-digit year-over-year revenue growth for both the fourth quarter and full year 2025, driven by sales of its bempedoic acid–based cardiovascular therapies and collaboration income.

The company recognized collaboration revenue that included a $90 million milestone payment from its Japanese partner Otsuka (approximately KRW 120 billion) and announced plans to expand its cardio-metabolic portfolio through the acquisition of Corstasis, the developer of the bumetanide nasal spray Enbumyst.

Under the terms of the Corstasis transaction, Esperion will pay $75 million in upfront cash (roughly KRW 100 billion), plus additional regulatory and commercial milestone payments, sales-based contingent consideration, and shared license revenues. Upon closing, Corstasis will become a wholly owned subsidiary of Esperion.

On the same day, Esperion’s shares rose in pre-market trading after its fourth-quarter revenue modestly beat consensus estimates and the Corstasis acquisition was announced—signaling that investors are focusing on both the company’s financial performance and its inorganic growth strategy.

U.S. financial and biotechnology media have highlighted Enbumyst as the first nasal-spray loop diuretic approved by the FDA (September 2025) for treating edema associated with congestive heart failure. They note its potential to capture a multibillion-dollar slice of the U.S. heart-failure market.

Headquartered in Michigan, Esperion is a cardiovascular and metabolic disease–focused biotech company whose core products, NEXLETOL and NEXLIZET, are oral bempedoic acid–class therapies designed to lower LDL cholesterol.

Against a backdrop of global aging and rising obesity rates, demand for cardiovascular and heart-failure treatments is growing. Biopharma companies are competing to bolster their cardio-metabolic portfolios with oral LDL-lowering agents and innovative diuretics.